CRISPR THERAPEUTICS AG Revenues
CRISPR THERAPEUTICS AG (CRSP) reported Revenues of $157.00 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-04-28.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2020-04-28
- CRISPR THERAPEUTICS AG revenues for the quarter ending 2020-03-31 was $157.00K, a 52.13% decline year-over-year.
- CRISPR THERAPEUTICS AG revenues for the quarter ending 2019-12-31 was $77.02M, a 66870.43% increase year-over-year.
- CRISPR THERAPEUTICS AG revenues for the quarter ending 2019-09-30 was $211.93M, a 37542.63% increase year-over-year.
- CRISPR THERAPEUTICS AG revenues for the quarter ending 2019-06-30 was $318.00K, a 70.77% decline year-over-year.
- CRISPR THERAPEUTICS AG revenues for fiscal 2019 was $289.59M, a 9169.85% increase from fiscal 2018.
- CRISPR THERAPEUTICS AG revenues for fiscal 2018 was $3.12M, a 92.38% decline from fiscal 2017.
- CRISPR THERAPEUTICS AG revenues for fiscal 2017 was $41.00M, a 693.90% increase from fiscal 2016.
- CRISPR THERAPEUTICS AG revenues for fiscal 2016 was $5.16M, a 1990.69% increase from fiscal 2015.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2020-03-31 | $157.00K 10-Q · filed 2020-04-28 | $77.17M derived: sum of 2 quarters · filed 2020-04-28 | $289.10M derived: sum of 3 quarters · filed 2020-04-28 | $289.42M derived: sum of 4 quarters · filed 2020-04-28 |
| 2019-12-31 | $77.02M 10-K · filed 2020-02-12 | $288.94M derived: sum of 2 quarters · filed 2020-02-12 | $289.26M derived: sum of 3 quarters · filed 2020-02-12 | $289.59M 10-K · filed 2020-02-12 |
| 2019-09-30 | $211.93M 10-K · filed 2020-02-12 | $212.25M derived: sum of 2 quarters · filed 2020-02-12 | $212.57M 10-Q · filed 2019-10-28 | $212.69M derived: sum of 4 quarters · filed 2020-04-28 |
| 2019-06-30 | $318.00K 10-K · filed 2020-02-12 | $646.00K 10-Q · filed 2019-07-29 | $761.00K derived: sum of 3 quarters · filed 2020-04-28 | $1.32M derived: sum of 4 quarters · filed 2020-04-28 |
| 2019-03-31 | $328.00K 10-Q · filed 2020-04-28 | $443.00K derived: sum of 2 quarters · filed 2020-04-28 | $1.01M derived: sum of 3 quarters · filed 2020-04-28 | $2.09M derived: sum of 4 quarters · filed 2020-04-28 |
| 2018-12-31 | $115.00K 10-K · filed 2020-02-12 | $678.00K derived: sum of 2 quarters · filed 2020-02-12 | $1.77M derived: sum of 3 quarters · filed 2020-02-12 | $3.12M 10-K · filed 2020-02-12 |
| 2018-09-30 | $563.00K 10-K · filed 2020-02-12 | $1.65M derived: sum of 2 quarters · filed 2020-02-12 | $3.01M 10-Q · filed 2019-10-28 | $35.33M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | $1.09M 10-K · filed 2020-02-12 | $2.45M 10-Q · filed 2019-07-29 | $34.77M derived: sum of 3 quarters · filed 2020-02-12 | $37.16M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | $1.36M 10-K · filed 2020-02-12 | $33.68M derived: sum of 2 quarters · filed 2020-02-12 | $36.07M derived: sum of 3 quarters · filed 2020-02-12 | $39.65M derived: sum of 4 quarters · filed 2020-02-12 |
| 2017-12-31 | $32.33M 10-K · filed 2019-02-25 | $34.71M derived: sum of 2 quarters · filed 2019-02-25 | $38.29M derived: sum of 3 quarters · filed 2019-02-25 | $41.00M 10-K · filed 2020-02-12 |
| 2017-09-30 | $2.39M 10-K · filed 2019-02-25 | $5.97M derived: sum of 2 quarters · filed 2019-02-25 | $8.67M 10-Q · filed 2018-11-07 | $11.02M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-06-30 | $3.58M 10-K · filed 2019-02-25 | $6.29M 10-Q · filed 2018-08-07 | $8.63M derived: sum of 3 quarters · filed 2019-02-25 | $10.18M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-03-31 | $2.70M 10-K · filed 2019-02-25 | $5.05M derived: sum of 2 quarters · filed 2019-02-25 | $6.60M derived: sum of 3 quarters · filed 2019-02-25 | $7.39M derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | $2.34M 10-K · filed 2018-03-08 | $3.89M derived: sum of 2 quarters · filed 2018-03-08 | $4.69M derived: sum of 3 quarters · filed 2018-03-08 | $5.16M 10-K · filed 2019-02-25 |
| 2016-09-30 | $1.55M 10-K · filed 2018-03-08 | $2.34M derived: sum of 2 quarters · filed 2018-03-08 | $2.82M 10-Q · filed 2017-11-08 | $3.07M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $795.00K 10-K · filed 2018-03-08 | $1.27M 10-Q · filed 2017-08-10 | $1.52M derived: sum of 3 quarters · filed 2018-03-08 | |
| 2016-03-31 | $476.00K 10-K · filed 2018-03-08 | $723.00K derived: sum of 2 quarters · filed 2018-03-08 | ||
| 2015-12-31 | $247.00K 10-K · filed 2017-03-10 | $247.00K 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |